"Fluorodeoxyglucose F18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
| Descriptor ID |
D019788
|
| MeSH Number(s) |
D09.254.229.500
|
| Concept/Terms |
Fluorodeoxyglucose F18- Fluorodeoxyglucose F18
- F18, Fluorodeoxyglucose
- 18F-FDG
- Fluorodeoxyglucose F 18
- F 18, Fluorodeoxyglucose
- Fludeoxyglucose F 18
- F 18, Fludeoxyglucose
- Fluorine-18-fluorodeoxyglucose
- Fluorine 18 fluorodeoxyglucose
- 18F Fluorodeoxyglucose
- Fluorodeoxyglucose, 18F
- 18FDG
|
Below are MeSH descriptors whose meaning is more general than "Fluorodeoxyglucose F18".
Below are MeSH descriptors whose meaning is more specific than "Fluorodeoxyglucose F18".
This graph shows the total number of publications written about "Fluorodeoxyglucose F18" by people in this website by year, and whether "Fluorodeoxyglucose F18" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 2 | 3 |
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorodeoxyglucose F18" by people in Profiles.
-
18 F-fludeoxyglucose positron emission computed tomography (18 F-FDG-PET/CT) versus 68 Ga-DOTATATE-PET/CT in patients with head and neck cancer: Comparisons and implications for treatment. Head Neck. 2023 02; 45(2):347-354.
-
Positron Emission Tomography (PET) with 18F-FGA for Diagnosis of Myocardial Infarction in a Coronary Artery Ligation Model. Mol Imaging. 2022; 2022:9147379.
-
Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685. J Clin Oncol. 2019 07 10; 37(20):1704-1712.
-
Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology. 2018 04; 287(1):176-184.
-
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nat Commun. 2017 05 26; 8:15503.
-
Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology. 2017 05; 283(2):450-459.
-
Quantitative evaluation of correlation of dose and FDG-PET uptake value with clinical chest wall complications in patients with lung cancer treated with stereotactic body radiation therapy. J Xray Sci Technol. 2015; 23(6):727-36.
-
A "dose on demand" Biomarker Generator for automated production of [(18)F]F(-) and [(18)F]FDG. Appl Radiat Isot. 2014 Jul; 89:167-75.
-
Preclinical evaluation of 4-[3,5-bis(2-chlorobenzylidene)-4-oxo-piperidine-1-yl]-4-oxo-2-butenoic acid, in a mouse model of lung cancer xenograft. Br J Pharmacol. 2013 Dec; 170(7):1436-48.
-
Gemcitabine-associated large vessel vasculitis presenting as fever of unknown origin. J Clin Rheumatol. 2010 Jun; 16(4):181-2.